Using a subcutaneous PDAC mouse model, Zhang et al. have demonstrated that ATM inhibition improves the therapeutic efficacy of anti-PD-L1, which is further improved in combination with RT (8 Gy), resulting in enhanced tumor immunogenicity. Here, CD274 is linked to neoplasm.